Alliance A071701: Genomically guided treatment trial in brain metastases., page-23

Nothing specific from the company about tonight. Although discussions do take place from Priscilla Brastanious and others, from time to time, on this ALLIANCE Trial.

So why are were interested tonight.

43% of all Brain Metastases have these PI3k cancer mutations, which Paxalisib is designed to treat.

So nearly half the people in the world who develop Brain Mets may be assisted by the KZA drug....we still don't know if it works for sure.....so just looking for information, anything at all from PB soon, as to progress on the landmark trial, for which she is in charge.

Nobody would dispute the fact that if Paxalisib is approved the drug itself would be worth about US$15 b.

Additionally PB has always presented very positive pre clinic data on our drug. Mention of Pi3k/mTOR is what is relevant tonight.